ClinicalTrials.gg
CompletedNCT07423897Updated Oct 19, 2026

Consumer Health Study Aims to Evaluate the Safety, Tolerability and Impact of ED02 Probiotic Supplement on Gastrointestinal Outcomes

An interventional study of Bifidobacterium pseudocatenulatum and Placebo in Gastrointestinal and Gut Health, sponsored by Synbiotic Health. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Synbiotic Health · Not applicable, Interventional, and Other

How we know

Updated Oct 19, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The Study Team identified Bifidobacterium pseudocatenulatum ED02 as a safe and effective probiotic strain isolated from a healthy human donor. Research by the Study Team indicates that this strain lacks harmful genetic traits and can successfully mitigate infections from hypervirulent pathogens like Klebsiella pneumoniae without adverse effects.

Read the detailed description

Species within the genus Bifidobacterium are vital components of the human microbiome across all life stages, with B. pseudocatenulatum being a primary species found in adults. The Study Team highlighted that the specific strain ED02 was isolated from the fecal matter of a healthy adult after being enriched with the prebiotic xylooligosaccharides. To ensure the strain's safety for therapeutic use, the Study Team performed genome sequencing, which confirmed the absence of any virulence factors or antibiotic resistance genes. Furthermore, in vivo testing conducted by the Study Team demonstrated that ED02 provided significant health improvements in mice infected with hypervirulent Klebsiella pneumoniae. Throughout these trials, the Study Team observed no adverse events, supporting the potential of ED02 as a safe intervention for gastrointestinal and systemic health.

02

Conditions studied

  • Gastrointestinal
  • Gut Health

Keywords

  • Gastrointestinal
  • Gut Health
  • GI
  • Probiotic
03

In context

Lead sponsor

Synbiotic Health is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years and older, inclusive.
  • Willingness to refrain from taking probiotics or prebiotics during the study period.
  • Interested in understanding more about their gut health and the use of probiotic products.
  • If taking any OTC or prescription medications for anxiety (e.g. magnesium, anticholinergics, Buspirone, Tricyclics, MAOIs,) or other class of medication for anxiety, must be on a stable dose for at least 4 weeks prior to randomization and throughout the course of the study.
  • If using any cannabis-containing products, must be on a stable dose regimen for at least 4 weeks prior to randomization and throughout the course of the study.
  • If using any nicotine-containing products, must be on a stable regimen for at least 4 weeks prior to randomization and throughout the course of the study.
  • Willing to practice a reliable method of for the duration of the study.
  • In good general health at the time of screening (Investigator discretion).
  • Able to read and understand English.
  • Able to read, understand, and provide .
  • Able to use a personal smartphone device and download Chloe by People Science.
  • Able to receive shipment of the product at an address within the United States.
  • Able to complete study assessments over the course of up to 15 weeks.

Exclusion criteria

Exclusion Criteria:

Any potential participants who:

  • Do not have a personal smartphone, internet access, or unwilling to download Chloe.
  • Currently on a carnivore diet, raw food diet, fruitarian, liquid diet (does not include vegans or vegetarians).
  • Plan to make major changes in their diet during the study period.
  • Are not willing to complete stool samples.
  • Concomitant Therapies:

    1. Participants receiving any therapies or treatments within 30 days prior to randomization.
    2. Participants currently taking or have taken antibiotics, probiotic, or prebiotic supplements within the past 4 weeks prior to randomization.
    3. Participants using immunomodulating supplements, medications, systemic , antifungals or other medications known to significantly impact gastrointestinal function or microbiota.
    4. Participants currently taking fiber supplements
    5. Participants currently taking laxatives
    6. Participants taking chronic NSAIDs
    7. Participants taking Metformin
  • Other Illnesses or Conditions: Participants who have the following comorbidities or gastrointestinal illnesses are excluded:

    1. Participants with a clinical diagnosis of any gastrointestinal illness, including but not limited to:

      • Inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
      • Gastroesophageal reflux disease (GERD)
      • Gastric or duodenal ulcers
      • Celiac disease
      • Diverticular disease
      • Chronic pancreatitis
      • Gastroparesis
      • Severe liver disease (e.g., cirrhosis, hepatitis, NAFLD acceptable)
      • Gallbladder disease (e.g., cholecystitis, cholelithiasis)
      • Gastrointestinal cancer (Colorectal, Intestinal, Stomach, Liver, Gallbladder)
    2. Participants with a known or suspected gastrointestinal infection, such as:

      • Clostridium difficile infection
      • Helicobacter pylori infection
      • Parasitic infections (e.g., Giardia, Cryptosporidium)
    3. Participants with a history of gastrointestinal bleeding or perforation.
    4. Participants with conditions, such as:

      • Lupus
      • Multiple sclerosis
      • Rheumatoid Arthritis
    5. Participants with an immunocompromised status.
    6. Participants with uncontrolled diabetes.
    7. Participants with a history of gastrointestinal surgery, excluding appendectomy and cholecystectomy.
    8. Currently diagnosed with Alcohol Use Disorder and/or Substance Use Disorder.
    9. Currently pregnant, planning to become pregnant in the next 3 months, or breastfeeding.
    10. Any underlying medical conditions or comorbidities that may confound the assessment of digestive symptoms or the evaluation of the study outcomes.
    11. Have a significant illness, disease or condition which, in the opinion of the principal investigator, may impact their ability to participate in the study or impact the study outcomes.
  • Known or previous allergic reaction to microcrystalline cellulose, magnesium stearate, or silicon dioxide.
  • Are unlikely for any reason to be able to comply with the trial or considered unsuited for participation in the study by the Principal Investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
43 participants (actual)

Study arms

  • Placebo comparator
    Placebo Arm

    Matching Placebo

    Dietary Supplement: Placebo

  • Active comparator
    Study Product Arm

    Participants taking the Probiotic Supplement

    Dietary Supplement: Bifidobacterium pseudocatenulatum

Interventions

  • Dietary supplementBifidobacterium pseudocatenulatum

    Probiotic Supplement

  • Dietary supplementPlacebo

    Matching placebo

06

What researchers measure

Primary outcomes

  1. Impact and Tolerability

    The primary objective of the study is to evaluate the impact and tolerability of the probiotic study product. This is measured by assessment of the number, frequency, and severity of adverse events (AEs), serious adverse events (SAEs) and AE withdrawals reported over the study product/placebo use period.

    Time frame: 4 weeks

Secondary outcomes

  1. Gastrointestinal Symptoms

    To evaluate the impact of the probiotic study product on gastrointestinal symptom rating. This will be measured by using changes in mean Gastrointestinal Symptom Rating Scale (GSRS) scores between placebo and study product groups during the study period.

    Time frame: 6 weeks

  2. Daily Gastrointestinal Symptoms

    The goal is to evaluate the impact of the probiotic study product on daily gastrointestinal symptoms by using the changes in average scores of gastrointestinal symptoms (i.e. flatulence, bloating, abdominal discomfort) between placebo and study product group as measured by daily survey questions.

    Time frame: 4 weeks

  3. Impact on Gut Microbiota

    To evaluate the impact of the probiotic study product on gut microbiota composition, diversity, and function assessed using metagenomic sequencing of fecal samples by using the changes from baseline to end treatment at Week 4 between study product and placebo group. Sample obtained at 2 weeks after the last dose will be compared as well.

    Time frame: 6 weeks

  4. Safety of Probiotic (Blood Hematology Profile)

    To evaluate the impact of the probiotic on safety by using changes in blood parameters from baseline to end of treatment between placebo and probiotic study groups. Blood biomarkers assessed by Complete Blood Count (CBC).

    Time frame: 4 weeks

  5. Safety of Probiotic (Blood Chemistry Profile)

    To evaluate the impact of the probiotic on safety by using changes in blood biomarkers from baseline to end of treatment between placebo and probiotic study groups. Blood biomarkers assessed by Comprehensive Metabolic Panel (CMP).

    Time frame: 4 weeks

07

Study locations

1 site
  • People Science, Inc.
    Los Angeles, California 90045, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2026 to primary completion in Jul 2026, 5 months.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jul 2026, on Oct 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2026
First posted
Feb 20, 2026
StartActual
Feb 2, 2026
Primary completionActual
Jul 28, 2026was Jun 2026
CompletionActual
Aug 3, 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 19, 2026
Primary completion
Jun 17, 2026→Jul 28, 2026 (actual)
Oct 19, 2026
Study completion
Aug 31, 2026→Aug 3, 2026 (actual)
Oct 19, 2026
Enrollment
35 (estimated)→43 (actual)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Active, not recruiting→Completed
    Primary completion Jun 17, 2026→Jul 28, 2026 (now actual)
    Study completion Aug 31, 2026→Aug 3, 2026 (now actual)
    Enrollment 35 (estimated)→43 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07423897
Lead sponsor
Synbiotic Health
Collaborators
People Science, Inc.
Responsible party
Sponsor
First posted
Feb 20, 2026
Start date
Feb 2, 2026
Primary completion
Jul 28, 2026
Completion
Aug 3, 2026
Last update
Oct 19, 2026

Study contacts

Noah Craft, M.D., Ph.D.
principal investigator · People Science, Inc.
Azure Grant
principal investigator · People Science, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion